The incidence of
auto-immune diseases is increasing nowa- days. Despite of the development of
diagnosis and management of diseases, they remained chronic diseases.
The patient’s
lifespan expansion requires long-term treatment with harmful agents, such as
Methotrexate or other immuno-suppressive drugs. The Methotrexate
toxicities are based on the duration and cumulative dosing of drug, and the
combination with other drugs.
Myelosuppression
and consequent pancytopenia is the most frequent hematologic toxicity, which
occur mostly later during low dose methotrexate administration. We demonstrate
three cases of low dose Methotrexate toxicity in older patients with rheumatoid
arthritis and psoriasis.
No comments:
Post a Comment